Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Issued (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Shares Issued for 3 consecutive years, with -$15.3 million as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 31.52% to -$15.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 7.35% year-over-year, with the annual reading at $1.6 million for FY2025, 7.35% down from the prior year.
  • Shares Issued hit -$15.3 million in Q4 2025 for NewAmsterdam Pharma, down from $5.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $8.8 million in Q1 2024 to a low of -$15.3 million in Q4 2025.
  • Historically, Shares Issued has averaged $1.2 million across 3 years, with a median of $4.0 million in 2024.
  • Biggest five-year swings in Shares Issued: surged 303.67% in 2024 and later tumbled 31.52% in 2025.
  • Year by year, Shares Issued stood at $8.5 million in 2023, then crashed by 236.82% to -$11.7 million in 2024, then tumbled by 31.52% to -$15.3 million in 2025.
  • Business Quant data shows Shares Issued for NAMS at -$15.3 million in Q4 2025, $5.6 million in Q3 2025, and $3.4 million in Q2 2025.